oncology

<![if lt IE 4]> <script src="http://servedbyadbutler.com/adserve/;ID=101843;size=468x60;setID=73431;type=js" type="text/javascript"> </script> <noscript> <a href="http://servedbyadbutler.com/go2/;ID=101843;size=468x60;setID=73431"> <img src="http://servedbyadbutler.com/adserve/;ID=101843;size=468x60;setID=73431;type=img" border="0" height="60" width="468" alt=""></a> </noscript><![endif]>

THLD Lazard Research Report

By WallStArb - Posted on August 21st, 2009

Tagged:

NOTE: You can download the attached FULL PDF

We upgrade our rating to BUY from HOLD based on our increased conviction for compelling Phase II results for TH-302 in combination with standard chemotherapeutics.

Average:

Your rating: None Average: 5 (1 vote)

User login

Navigation

Who's new

GeorgAlvinTT
revaDedia
adrienmcgowan
adansharp259
Ralge

Copyright © 1997 - 2008 Financial Chat, Inc. All Rights Reserved
<![if lt IE 4]> <script src="http://servedbyadbutler.com/adserve/;ID=101843;size=468x60;setID=73431;type=js" type="text/javascript"> </script> <noscript> <a href="http://servedbyadbutler.com/go2/;ID=101843;size=468x60;setID=73431"> <img src="http://servedbyadbutler.com/adserve/;ID=101843;size=468x60;setID=73431;type=img" border="0" height="60" width="468" alt=""></a> </noscript><![endif]>

oncology

THLD Lazard Research Report

User login

Navigation

site info

Who's online

Online users

Who's new